NorthStrive files two patents for muscle-loss drugs in spaceflight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
August 21, 2026 9:30 AM EDTNew Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrives Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health and Animal Health Applications
The filings are intended to position EL-22 and EL-32 as potential muscle-preservation platforms not only for large terrestrial markets, but also for the emerging medical requirements associated with sustained human presence in space
NEWPORT BEACH, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq:... More
